Hemopure Study Set For Committee Review, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopure's oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)] will be the topic of an FDA advisory committee July 14, the firm says
You may also be interested in...
Biopure Hemopure Advisory Committee For Hemorrhagic Shock Expected By September
The FDA committee would likely discuss circumstances under which the agency could lift a clinical hold that has been on the Hemopure trial since the IND was submitted in June 2005.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.